MarketCapExport financials
Phreesia (PHR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Phreesia Balance Sheet 2026-2011 | PHR
Brief overview of Phreesia's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2022 and 2026.
Assets added +34.2%, reaching $663.8 million from $494.5 million five periods earlier; annual growth near 7.6% remained solid.
Liabilities grew faster than assets: +323.1% versus +34.2%. A substantial part of expansion was externally funded.
Internal capital represents 50.8% of the balance sheet, previously 84.4%. This is a strong capital position.
Negative net debt of -$69.9 million means cash holdings are larger than debt obligations.
Cash accounts for 11.1% of assets versus 63.5% initially. The change indicates the degree of financial flexibility.
The balance sheet carries negative retained earnings of -$799.2 million. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
Phreesia's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Phreesia
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-69.9 M | -81.3 M | -84 M | -176 M | -312 M | -211 M | -66.5 M | 26.5 M | 10.1 M | - | - | - | - | - | - | - |
Long Term Debt |
2.66 M | 1.94 M | 3.15 M | 246 K | 360 K | 6.47 M | 19.4 M | 27.9 M | 19.5 M | - | - | - | - | - | - | - |
Long Term Debt Current |
1.25 M | 964 K | 393 K | 934 K | 1.28 M | 1.09 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 21.5 M | 242 M | 200 M | - | - | - | - | - | - | - |
Total Current Liabilities |
183 M | 114 M | 110 M | 79 M | 68.4 M | 55 M | 35.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
327 M | 124 M | 119 M | 82.2 M | 77.2 M | 63.4 M | 56.9 M | 270 M | 225 M | - | - | - | - | - | - | - |
Deferred Revenue |
49.5 M | 32.8 M | 24.1 M | 17.7 M | 16.5 M | 10.8 M | 5.4 M | 6.49 M | 4.89 M | - | - | - | - | - | - | - |
Retained Earnings |
-799 M | -801 M | -743 M | -606 M | -430 M | -312 M | -284 M | -211 M | -168 M | - | - | - | - | - | - | - |
Total Assets |
664 M | 388 M | 370 M | 370 M | 494 M | 327 M | 159 M | 59.3 M | 57.1 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
73.8 M | 84.2 M | 87.5 M | 177 M | 314 M | 219 M | 90.3 M | 1.54 M | 10.5 M | - | - | - | - | - | - | - |
Book Value |
337 M | 265 M | 251 M | 288 M | 417 M | 263 M | 102 M | -211 M | -168 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
337 M | 265 M | 251 M | 288 M | 417 M | 263 M | 102 M | -211 M | -168 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Phreesia
| 2027-Q2 | 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.11 M | 612 K | 646 K | 964 K | 1.3 M | 1.63 M | 134 K | 2.32 M | 1.3 M | 1.63 M | 349 K | 2.32 M | - | 2.88 M | 1.28 M | 3.66 M | 3.88 M | 309 K | 2.72 M | 183 K | 158 K | 544 K | 1.63 M | 504 K | 469 K | 781 K | 19.4 M | 22.9 M | 23.5 M | 19.5 M | 27.9 M | 19.4 M | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
327 M | 307 M | 124 M | 103 M | 111 M | 118 M | 119 M | 121 M | 111 M | 118 M | 82.2 M | 121 M | - | 119 M | 77.2 M | 110 M | 93.4 M | 90.2 M | 82.2 M | 76.9 M | 77.5 M | 77.9 M | 63.4 M | 71.2 M | 64.7 M | 57.9 M | 56.9 M | 68.4 M | 62.6 M | 61.4 M | 63.7 M | 53.4 M | 60.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
49.5 M | 39.6 M | 32.8 M | 29.7 M | 26.9 M | 31.1 M | 24.1 M | 22.2 M | 26.9 M | 31.1 M | 17.7 M | 22.2 M | - | 24.1 M | 16.5 M | 22 M | 16.4 M | 17.9 M | 17.7 M | 13.9 M | 17.2 M | 17.8 M | 10.8 M | 12.4 M | 12.9 M | 13.2 M | 5.4 M | 6.62 M | 6.26 M | 6.63 M | 6.49 M | 5.33 M | 5.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-799 M | -796 M | -801 M | -800 M | -805 M | -805 M | -743 M | -795 M | -805 M | -805 M | -606 M | -795 M | - | -763 M | -430 M | -712 M | -680 M | -644 M | -606 M | -568 M | -528 M | -481 M | -312 M | -383 M | -347 M | -323 M | -284 M | -304 M | -297 M | -291 M | -211 M | -281 M | -278 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
664 M | 666 M | 388 M | 423 M | 409 M | 400 M | 370 M | 376 M | 409 M | 400 M | 370 M | 376 M | - | 372 M | 494 M | 375 M | 340 M | 354 M | 370 M | 397 M | 426 M | 459 M | 327 M | 529 M | 551 M | 561 M | 159 M | 338 M | 160 M | 161 M | 59.3 M | 156 M | 163 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
84.2 M | 76.4 M | 177 M | 106 M | 98.3 M | 90.9 M | 314 M | 81.7 M | 98.3 M | 90.9 M | 219 M | 81.7 M | 81.8 M | 79.5 M | 90.3 M | 103 M | 128 M | 150 M | 177 M | 210 M | 241 M | 269 M | 219 M | 400 M | 440 M | 451 M | 90.3 M | 254 M | 84.2 M | 90.3 M | 1.54 M | 91.4 M | 100 M | 5.91 M | 10.5 M | 2.61 M | 4.43 M | - | 2.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
337 M | 359 M | 265 M | 320 M | 298 M | 282 M | 251 M | 255 M | 298 M | 282 M | 288 M | 255 M | - | 253 M | 417 M | 265 M | 247 M | 264 M | 288 M | 320 M | 348 M | 381 M | 263 M | 458 M | 487 M | 503 M | 102 M | 270 M | 97.7 M | 99.9 M | -4.48 M | 102 M | 103 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
265 M | 359 M | 288 M | 320 M | 298 M | 282 M | 417 M | 255 M | 298 M | 282 M | 263 M | 255 M | 251 M | 253 M | 102 M | 265 M | 247 M | 264 M | 288 M | 320 M | 348 M | 381 M | 263 M | 458 M | 487 M | 503 M | 102 M | 270 M | 97.7 M | 99.9 M | -211 M | 102 M | 103 M | -224 M | -168 M | - | -185 M | -173 M | -130 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Phreesia, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.44 | -0.92 % | $ 216 M |  USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.65 | -2.66 % | $ 115 M | USA |
 |
HealthStream
HSTM
|
$ 34.57 | -1.65 % | $ 1.04 B | USA |
 |
Omnicell
OMCL
|
$ 37.37 | -1.01 % | $ 1.72 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 8.98 | -1.91 % | $ 167 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.52 | -0.56 % | $ 1.25 B | USA |
 |
HealthEquity
HQY
|
$ 103.34 | -0.61 % | $ 8.9 B | USA |
 |
Schrödinger
SDGR
|
$ 24.58 | 3.28 % | $ 1.81 B | USA |
 |
Teladoc Health
TDOC
|
$ 6.18 | -2.6 % | $ 1.09 B | USA |
 |
Veeva Systems
VEEV
|
$ 318.06 | -1.51 % | $ 52.1 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.2 | -6.98 % | $ 4.1 M |  China |
 |
So-Young International
SY
|
$ 2.13 | 0.71 % | $ 166 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
$ 4.39 | -6.98 % | $ 501 M | USA |
 |
Progyny
PGNY
|
$ 28.34 | -2.17 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 73.51 | 2.74 % | $ 9.17 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
$ 7.25 | 31.34 % | $ 52.7 M | USA |